SC262 + cyclophosphamide + fludarabine

**SC262 + cyclophosphamide + fludarabine** is an experimental drug regimen composed of three distinct agents: SC262 (a code name for a specific investigational compound), cyclophosphamide (an alkylating agent), and fludarabine (a purine analog). Cyclophosphamide functions by cross-linking DNA and inhibiting cell division[2][3][4][7], while fludarabine inhibits DNA synthesis by acting as a nucleoside analog. This combination is designed to synergistically suppress hematologic malignancies via complementary cytotoxic and immunosuppressive effects. The regimen is most likely investigated for leukemia, lymphoma, and other hematologic cancers. However, details specific to SC262’s mechanism and developer are rarely available in public domain drug and trial registries; based on its code name, it is presumed to be an investigative compound possibly with immunomodulatory or cytotoxic function comparable to the other agents in this regimen.